Figure 2 Switching of biologic agents and biosimilars

Slides:

Advertisements

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advertisements

Figure 3 Low-grade inflammation in FGID

Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Patients cured of HCV infection

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Schematic outlining the results of Buffington et al.

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 High-resolution manometry of achalasia subtypes

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Pseudorelaxation as a consequence of

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

Figure 4 Functional luminal imaging probe

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 3 Lipid droplet formation and expansion

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 High-resolution manometry studies performed

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 2 Switching of biologic agents and biosimilars Figure 2 | Switching of biologic agents and biosimilars. Switching is a decision by the treating physician to exchange one medicine for another. Currently, physicians often need to decide about switching from the innovator biologic agent to a biosimilar. In the future, they will need to also consider a switch in the opposite direction (reverse-switch), or from one biosimilar to another (cross-switch). Danese, S. et al. (2016) Biosimilars in IBD: from theory to practice Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.155